Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference

11/25/2020 | 08:00am EST

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

A recording of the fireside chat will be accessible to institutional clients of Piper Sandler beginning December 1, 2020 via Piper Sandler’s event portal. The Company will be available for institutional investor meetings on December 1, 2020.

About VYNE Therapeutics Inc.
In March 2020, Menlo Therapeutics Inc. ("Menlo") and Foamix Pharmaceuticals Ltd. (“Foamix”) combined to form what is now known as VYNE Therapeutics Inc. VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit http://www.vynetherapeutics.com/ or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

CONTACT:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com

 


Primary Logo


© GlobeNewswire 2020
All news about VYNE THERAPEUTICS INC.
01/26Wall Street Wavers Pre-Bell Amid Earnings Deluge
MT
01/26VYNE THERAPEUTICS : Announces $50 Million Registered Direct Offering of Common S..
AQ
01/26VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K..
AQ
01/22VYNE THERAPEUTICS : Announces Contract Execution for AMZEEQ and ZILXI with Major..
AQ
01/21VYNE THERAPEUTICS : Signs Deal With Pharmacy Benefit Manager for FDA-Approved Sk..
MT
01/21VYNE THERAPEUTICS : Announces Contract Execution for AMZEEQ® (minocycline) and Z..
AQ
01/07VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
01/05VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Co..
AQ
2020VYNE THERAPEUTICS : Completes End-of-Phase 2 Meeting With FDA for FCD105 to Trea..
MT
2020VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for ..
GL
More news
Financials (USD)
Sales 2020 21,9 M - -
Net income 2020 -258 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,09x
Yield 2020 -
Capitalization 420 M 420 M -
Capi. / Sales 2020 19,2x
Capi. / Sales 2021 6,78x
Nbr of Employees 40
Free-Float -
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 5,93 $
Last Close Price 2,50 $
Spread / Highest target 300%
Spread / Average Target 137%
Spread / Lowest Target 20,0%
EPS Revisions